New Zealand Data Sheet

Name of Medicinal Product
Adenuric® Febuxostat

Description
ADENURIC® tablet is a potent, non purine, selective inhibitor of Xanthine Oxidase (XO) that prevents the normal oxidation of purines to uric acid.

The active ingredient in ADENURIC® is febuxostat, a 2-arylthiazole derivative. Its chemical name is 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5- carboxylic acid, and the chemical structure is:

```
\[\text{CHEMICAL STRUCTURE DIAGRAM}\]
```

CAS number: 144060-53-7
Molecular formula: C16H16N2O3S
Molecular weight: 316.37
Febuxostat belongs to the pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production (ATC code: M04AA03)

Presentation
ADENURIC® 80 mg and 120 mg tablets are pale yellow to yellow, film-coated, capsule shaped tablets, with “80” or “120” on one side. They are immediate release tablets containing 80 mg or 120 mg of febuxostat as the active substance.

Tablets contain the following inactive ingredients: Lactose monohydrate, Cellulose-microcrystalline, Magnesium stearate, Hydroxypropylcellulose, Croscarmellose sodium and Silicon dioxide. Core tablets are coated with Opadry II, Yellow, 85F42129 containing: Polyvinyl alcohol, Titanium dioxide, Macrogol 3350, Talc- purified and Iron oxide yellow.

Indications
ADENURIC® 80 mg
ADENURIC® is indicated for the treatment of chronic hyperuricaemia in patients with gout (including a history, or presence of, tophus and/or gouty arthritis).

ADENURIC® is indicated in adults.
ADENURIC® 120 mg
ADENURIC® is indicated for the treatment of chronic hyperuricaemia in patients with gout (including a history, or presence of, tophus and/or gouty arthritis).

ADENURIC® is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).

ADENURIC® is indicated in adults.

Dosage

Gout
The recommended oral dose of ADENURIC® is 80 mg once daily with or without food. If serum uric acid is > 6 mg/dl (357 µmol/l) after 2-4 weeks, ADENURIC® 120 mg once daily may be considered.

ADENURIC® works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dl (357µmol/l).

Gout flare prophylaxis of at least 6 months is recommended.

Tumor Lysis Syndrome
The recommended oral dose of ADENURIC® is 120 mg once daily without regard to food.

ADENURIC® should be started two days before the beginning of cytotoxic therapy and continued for a minimum of 7 days; however treatment may be prolonged up to 9 days according to chemotherapy duration as per clinical judgment.

Paediatric population
The safety and the efficacy of ADENURIC® in children aged below the age of 18 years have not been established. The use of febuxostat in children is not recommended.

Older people
No dose adjustment is required in the elderly.

Renal impairment
The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 ml/min). No dosage adjustment is necessary in patients with mild or moderate renal impairment.

Hepatic impairment
The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C).

Gout: The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.

Tumour Lysis Syndrome: in the pivotal Phase III trial (FLORENCE) only subjects with severe hepatic
insufficiency were excluded from trial participation. No dose adjustment was required for enrolled patients on the basis of hepatic function.

**Administration**

ADENURIC® is to be taken once daily without regard to food.

**Contraindications**

Hypersensitivity to febuxostat or to any other ingredients of the product listed at the beginning of this leaflet.

**Warnings and Precautions**

*Cardiovascular disorders*

*Treatment of chronic hyperuricaemia*

Treatment with febuxostat in patients with ischaemic heart disease or congestive heart failure is not recommended. A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists’ Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see Clinical Trial section for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase III studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure.

*Prevention and treatment of hyperuricaemia in patients at risk of TLS*

Patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome treated with ADENURIC® should be under cardiac monitoring as clinically appropriate.

*Medicinal product allergy / hypersensitivity*

Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens – Johnson Syndrome, toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases.

Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions. Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since
early withdrawal is associated with a better prognosis. If patient has developed allergic/hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must not be re-started in this patient at any time.

**Acute gouty attacks (gout flare)**

Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended.

If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.

**Xanthine deposition**

In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This has not been observed in the pivotal clinical study with ADENURIC® in the Tumor Lysis Syndrome. As there has been no experience with febuxostat, its use in patients with Lesch-Nyhan Syndrome is not recommended.

**Mercaptopurine/azathioprine**

Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine. Where the combination cannot be avoided patients should be closely monitored. A reduction of dosage of mercaptopurine or azathioprine is recommended in order to avoid possible haematological effects (see Interactions).

**Organ transplant recipients**

As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended.

**Theophylline**

Co-administration of febuxostat 80 mg and theophylline 400 mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section Interactions). Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. No data is available for febuxostat 120 mg.

**Liver disorders**

During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment.

**Thyroid disorders**

Increased TSH values (>5.5 μIU/ml) were observed in patients on long-term treatment with febuxostat (5.5%) in the long term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function.
Lactose
Febuxostat tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Use in Pregnancy and During Lactation
Pregnancy (Category B2)
Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/new born child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition. The potential risk for human is unknown. Febuxostat should not be used during pregnancy.

Fertility
In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility. The effect of ADENURIC® on human fertility is unknown.

Lactation
It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat should not be used while breastfeeding.

Effects on Ability to Drive and Use Machinery
Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of Febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC® does not adversely affect performance.

Adverse Effects
Adverse events are reported separately for Gout and Tumor Lysis Syndrome because of differences in the characteristics of the diseases.

Gout
The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience in gout patients are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, have occurred in the post-marketing experience.

Tabulated list of adverse reactions:
Common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and rare (≥1/10,000 to < 1/1000) adverse reactions occurring in patients treated with febuxostat are listed below. The frequencies are based on studies and post-marketing experience in gout patients.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience in gout patients.

| Blood and lymphatic system disorders | Rare  
Pancytopenia, thrombocytopenia  |
| Immune system disorders | Rare  
Anaphylactic reaction*, drug hypersensitivity*  |
| Endocrine disorders | Uncommon  
Blood thyroid stimulating hormone increased  |
| Eye disorders | Rare  
Blurred vision  |
| Metabolism and nutrition disorders | Common***  
Gout flares  
Diabetes mellitus, hyperlipidemia, decrease appetite, weight increase  
Rare  
Weight decrease, increase appetite, anorexia  |
| Psychiatric disorders | Uncommon  
Libido decreased, insomnia  
Rare  
Nervousness  |
| Nervous system disorders | Common  
Headache  
Uncommon  
Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoesthesia, hyposmia  |
| Ear and labyrinth disorders | Rare  
Tinnitus  |
| Cardiac disorders | Uncommon  
Atrial fibrillation, palpitations, ECG abnormal, left bundle branch block (see section Tumor Lysis Syndrome), sinus tachycardia (see section Tumor Lysis Syndrome)  |
| Vascular disorders | Uncommon  
Hypertension, flushing, hot flush, haemorrhage (see section Tumor Lysis Syndrome)  |
| Respiratory system disorders | Uncommon  
Dyspnoea, bronchitis, upper respiratory tract infection, cough  |
| Gastrointestinal disorders | Common  
Diarrhoea**, nausea  
Uncommon:  
Abdominal pain, abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort  
Rare  
Pancreatitis, mouth ulceration  |
| Hepato-biliary disorders | Common  
Liver function abnormalities**  
Uncommon  
Cholelithiasis  
Rare  
Hepatitis, jaundice*, liver injury*  |
| Skin and subcutaneous tissue disorders | Common  
Rash (including various types of rash reported with lower frequencies, see below)  
Uncommon  
Dermatitis, urticaria, pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash maculopapular, rash papular  
Rare  
Toxic epidermal necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with eosinophilia and systemic symptoms*, generalized rash (serious)*,  

erythema, exfoliative rash, rash follicular, rash vesicular, rash pustular, rash pruritic*, rash erythematous, rash morbilliform, alopecia, hyperhidrosis

Musculoskeletal and connective tissue disorders
Uncommon
Arthralgia, arthritis, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle tightness, bursitis
Rare
Rhabdomyolysis*, joint stiffness, musculoskeletal stiffness

Renal and urinary disorders
Uncommon
Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria
Rare
Tubulointerstitial nephritis*, micturition urgency

Reproductive system and breast disorder
Uncommon
Erectile dysfunction

General disorders and administration site conditions
Common
Oedema
Uncommon
Fatigue, chest pain, chest discomfort
Rare
Thirst

Investigations
Uncommon
Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatine increase, blood creatinine increase, haemoglobin decrease, blood urea increase, blood triglycerides increase, blood cholesterol increase, haematocrit decrease, blood lactate dehydrogenase increased, blood potassium increase
Rare
Blood glucose increased, activated partial thromboplastin time prolonged, red blood cell count decrease, blood alkaline phosphatase increase

* Adverse reactions coming from post-marketing experience
** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase III studies are more frequent in patients concomitantly treated with colchicine.
*** See section Clinical Trial Data for incidences of gout flares in the individual Phase 3 randomized controlled studies.

Description of selected adverse reactions

Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are characterised by progressive skin rashes associated with blisters or mucosal lesions and eye irritation. Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis).

Gout flares were commonly observed soon after the start of treatment and during the first months. Thereafter, the frequency of gout flare decreases in a time-dependent manner. Gout flare prophylaxis is recommended.

Tumor Lysis Syndrome

Summary of the safety profile

In the randomized, double-blind, Phase 3 pivotal FLORENCE (FLO-01) study comparing febuxostat with allopurinol (346 patients undergoing chemotherapy for haematologic malignancies and at intermediate-to-high risk of TLS), only 22 (6.4%) patients overall experienced adverse reactions,
namely 11 (6.4%) patients in each treatment group. The majority of adverse reactions were either mild or moderate.

Overall, the FLORENCE trial did not highlight any particular safety concern in addition to the previous experience with ADENURIC® in gout, with the exception of the following three adverse reactions (listed above in table 1).

**Cardiac disorders:**
Uncommon: Left bundle branch block, sinus tachycardia

**Vascular disorders:**
Uncommon: Haemorrhage

---

**Clinical Trial Data**

**Gout**
The efficacy of ADENURIC® was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study described below) that were conducted in 4101 patients with hyperuricaemia and gout. In each Phase 3 pivotal study, ADENURIC® demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were < 6.0 mg/dl (357 µmol/l). In the additional Phase 3 CONFIRMS study, for which results became available after the marketing authorisation for ADENURIC® was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was < 6.0 mg/dL at the final visit. No patients with organ transplant have been included in these studies.

**APEX Study:** The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study. One thousand and seventy-two (1072) patients were randomized: placebo (n=134), ADENURIC® 80 mg QD (n=267), ADENURIC® 120 mg QD (n=269), ADENURIC® 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine ≥1.5 mg/dl or 100 mg QD [n=10] for patients with a baseline serum creatinine >1.5 mg/dl and ≥2.0 mg/dl). Two hundred and forty mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose.

The APEX study showed statistically significant superiority of both the ADENURIC® 80 mg QD and the ADENURIC® 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10 treatment arm in reducing the sUA below 6 mg/dl (357 µmol/l) (see Table 2 and Figure 1).

**FACT Study:** The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients were randomized: ADENURIC® 80 mg QD (n=256), ADENURIC® 120 mg QD (n=251), or allopurinol 300 mg QD (n=253).

The FACT study showed the statistically significant superiority of both ADENURIC® 80 mg and ADENURIC® 120 mg QD treatment arms versus the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dl (357 µmol/l).

Table 2 summarises the primary efficacy endpoint results:
Table 2: Proportion of Patients with Serum Uric Acid Levels <6.0 mg/dl (357µmol/l) Last Three Monthly Visits

<table>
<thead>
<tr>
<th>Study</th>
<th>ADENURIC® 80 mg QD</th>
<th>ADENURIC® 120 mg QD</th>
<th>Allopurinol 300/100 mg QD1</th>
</tr>
</thead>
<tbody>
<tr>
<td>APEX (28 weeks)</td>
<td>48% * (n=262)</td>
<td>65%*, # (n=269)</td>
<td>22% (n=268)</td>
</tr>
<tr>
<td>FACT (52 weeks)</td>
<td>53%* (n=255)</td>
<td>62%* (n=250)</td>
<td>21% (n=251)</td>
</tr>
<tr>
<td>Combined Results</td>
<td>51%* (n=517)</td>
<td>63%*, # (n=519)</td>
<td>22% (n=519)</td>
</tr>
</tbody>
</table>

* results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine >1.5 and ≤2.0 mg/dl) or 300 mg QD (n=509) were pooled for analyses.

† p < 0.001 vs allopurinol, # p < 0.001 vs 80 mg

The ability of ADENURIC® to lower serum uric acid levels was prompt and persistent. Reduction in serum uric acid level to <6.0 mg/dl (357 µmol/l) was noted by the Week 2 visit and was maintained throughout treatment. The mean serum uric acid levels over time for each treatment group from the two pivotal Phase 3 studies are shown in Figure 1.

Figure 1 Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies

![Figure 1 Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies](image)

Note: 509 patients received allopurinol 300 mg QD; 10 patients with serum creatinine >1.5 and ≤2.0 mg/dl were dosed with 100 mg QD. (10 patients out of 268 in APEX study). 240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose.

CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol 300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were randomized: ADENURIC® 40 mg QD (n=757),
ADENURIC® 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). At least 65% of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period.

The proportion of patients with serum urate levels of < 6.0 mg/dL (357 µmol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.

**Primary endpoint in the sub-group of patients with renal impairment**

The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dl and 2.0 mg/dl). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100mg QD. ADENURIC® achieved the primary efficacy endpoint in 44% (80 mgQD), 45% (120 mg QD), and 60% (240 mg QD) of patients compared to 0% in the allopurinol 100 mg QD and placebo groups.

There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58 % in the normal renal function group and 55% in the severe renal dysfunction group).

An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to < 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied).

**Primary endpoint in the sub group of patients with sUA ≥ 10 mg/dl**

Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of ≥ 10 mg/dl. In this subgroup ADENURIC® achieved the primary efficacy endpoint (sUA< 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups.

In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA < 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.

**Clinical Outcomes: Proportion of patients requiring treatment for a gout flare**

APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%). Flares increased following the prophylaxis period and gradually decreased over time. Between 46% and 55% of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects.

FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects.
The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dl, <5.0 mg/dl, or <4.0 mg/dl compared to the group that achieved an average post-baseline serum urate level ≥6.0 mg/dl during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 - 52 intervals).

During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31% and 25% for the febuxostat 80 mg and allopurinol groups, respectively. No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups.

**Long-term, open label extension Studies**

EXCEL Study (C02-021): The Excel study was a three years Phase 3, open label, multicenter, randomised, allopurinol-controlled, safety extension study for patients who had completed the pivotal Phase 3 studies (APEX or FACT). A total of 1086 patients were enrolled: ADENURIC® 80 mg QD (n=649), ADENURIC® 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145). About 69 % of patients required no treatment change to achieve a final stable treatment. Patients who had 3 consecutive sUA levels >6.0 mg/dl were withdrawn.

Serum urate levels were maintained over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA <6 mg/dL at Month 36).

Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96 % of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36. 46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.

FOCUS Study (TMX-01-005) was a 5 years Phase II, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004. 116 patients were enrolled and received initially febuxostat 80 mg QD. 62 % of patients required no dose adjustment to maintain sUA<6 mg/dL and 38 % of patients required a dose adjustment to achieve a final stable dose. The proportion of patients with serum urate levels of <6.0 mg/dL (357 µmol/l) at the final visit was greater than 80% (81-100%) at each febuxostat dose.

During the Phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). These rates were similar to the rates reported on allopurinol (4.2%) Increased TSH values (>5.5µIU/ml) were observed in patients on long-term treatment with febuxostat (5.5%) and patients with allopurinol (5.8%) in the long term open label extension studies.

**Tumor Lysis Syndrome**

The efficacy and safety of ADENURIC® in the prevention and treatment of Tumor Lysis Syndrome was evaluated in the FLORENCE (FLO-01) study. ADENURIC® showed a superior and faster urate lowering activity compared to allopurinol.

FLORENCE was a randomized (1:1), double blind, phase III, pivotal trial comparing ADENURIC® 120 mg once daily with allopurinol 200 to 600 mg daily (mean allopurinol daily dose [± standard deviation]: 349.7 ± 112.90 mg) in terms of control of serum uric acid level. Eligible patients had to
be candidates for allopurinol treatment or have no access to rasburicase. Primary endpoints were serum uric acid area under the curve (AUC sUA1-8) and change in serum creatinine (sC) level both from baseline to Day 8.

Overall, 346 patients with haematological malignancies undergoing chemotherapy and at intermediate / high risk of Tumor Lysis Syndrome were included. Mean AUC sUA1 8 (mgxh/dl) was significantly lower with ADENURIC® (514.0 ± 225.71 vs 708.0 ± 234.42; least square means difference: -196.794 [95% confidence interval: -238.600; -154.988]; p < .0001). Furthermore, the mean serum uric acid level was significantly lower with ADENURIC® since the first 24 hours of treatment and at any following time point. No significant difference in mean serum creatinine change (%) occurred between ADENURIC® and allopurinol (-0.83 ± 26.98 vs -4.92 ± 16.70 respectively; least square means difference: 4.0970 [95% confidence interval: -0.6467; 8.8406]; p=0.0903). With regard to secondary endpoints, no significant difference was detected in terms of incidence of laboratory TLS (8.1% and 9.2% in ADENURIC® and allopurinol arm, respectively; relative risk: 0.875 [95% confidence interval: 0.4408; 1.7369]; p=0.8488) nor of clinical TLS (1.7% and 1.2% in ADENURIC® and allopurinol arm, respectively; relative risk: 0.994 [95% confidence interval: 0.9691; 1.0199]; p=1.0000). Incidence of overall treatment-emergent signs and symptoms and adverse drug reactions was 67.6% vs 64.7% and 6.4% vs 6.4% with ADENURIC® and allopurinol respectively. In the FLORENCE study ADENURIC® demonstrated a superior control of serum uric acid level compared to allopurinol in patients scheduled to receive the latter drug. No data comparing ADENURIC® with rasburicase are currently available.

The efficacy and safety of febuxostat has not been established in patients with acute severe TLS, e.g. in patients who failed on other urate lowering therapies.

### Interactions Interaction with Other Medicinal Products

**Mercaptopurine/azathioprine**

On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to toxicity (see warning and precautions). Drug interaction studies of febuxostat with drugs that are metabolized by XO have not been performed.

Drug interaction studies of febuxostat with cytotoxic chemotherapy have not been conducted.

In the Tumor Lysis Syndrome pivotal trial febuxostat 120 mg daily was administered to patients undergoing several chemotherapy regimens, including monoclonal antibodies. However, drug-drug and drug-disease interactions were not explored during this study. Therefore, possible interactions with any concomitantly administered cytotoxic drug cannot be ruled out.

**Rosiglitazone/CYP2C8 substrates**

Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo. Thus, coadministration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.
**Theophylline**

An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors. The results of the study showed that the co-administration of febuxostat 80 mg QD with theophylline 400 mg single dose has no effect on the pharmacokinetics or safety of theophylline. Therefore no special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.

**Naproxen and other inhibitors of glucuronidation**

Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen 250mg twice daily was associated with an increase in febuxostat exposure (Cmax 28%, AUC 41% and t1/2 26%). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically significant increase in adverse events.

Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary.

**Inducers of glucuronidation**

Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.

**Colchicine/indometacin/hydrochlorothiazide/warfarin**

Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.

No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.

No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of febuxostat.

**Desipramine/CYP2D6 substrates**

Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in healthy subjects, 120 mg ADENURIC® QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.

**Antacids**

Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32%
decrease in Cmax, but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.

**Overdose**

In case of overdose, immediately contact the Poisons Information Centre (in Australia, call 13 11 26; in New Zealand call 0800 764 766) for advice.

**Further Information**

**Pharmacology**

Febuxostat belongs to the pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production (ATC code: M04AA03)

**Pharmacokinetics**

**General**

In healthy subjects, maximum plasma concentrations (Cmax) and area under the plasma concentration time curve (AUC) of febuxostat increased proportionally following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of 10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination half-life \((t_{1/2})\) of approximately 5 to 8 hours.

Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricemia and gout, treated with ADENURIC® 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout.

**Absorption**

Febuxostat is rapidly \((t_{max} \text{ of } 1.0-1.5 \text{ h})\) and well absorbed (at least 84%). After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 µg/ml, and 5.0-5.3 µg/ml, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied.

Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49% and 38% decrease in Cmax and a 18% and 16% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, ADENURIC® may be taken without regard to food.

**Distribution**

The apparent steady state volume of distribution \((V_{ss}/F)\) of febuxostat ranges from 29 to 75 l after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2%,
(primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82% to 91%.

**Metabolism**

Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans. In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.

**Excretion**

Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of 14C-labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).

**Special populations**

**Renal impairment**

Following multiple doses of 80 mg of ADENURIC® in patients with mild, moderate or severe renal impairment, the Cmax of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 µg h/ml in the normal renal function group to 13.2 µg.h/ml in the severe renal dysfunction group. The Cmax and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment.

**Hepatic impairment**

Following multiple doses of 80 mg of ADENURIC® in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the Cmax and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).

**Age**

There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of ADENURIC® in elderly as compared to younger healthy subjects.

**Gender**

Following multiple oral doses of ADENURIC®, the Cmax and AUC were 24% and 12% higher in females than in males, respectively. However, weight-corrected Cmax and AUC were similar between the genders. No dose adjustment is needed based on gender.
Mechanism of action:
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an in vitro inhibition Ki value less than one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.

Pharmaceutical Information

Shelf Life
The expiry date of the product is indicated on the packaging. 3 years from date of manufacture.

Storage
Store below 30°C.

Do not use the product after the expiration date.

Keep the medicine out of the reach of children.

Package Quantities
ADENURIC® tablets are packed in clear (Aclar/PVC/Aluminium) blisters containing 14 tablets.
ADENURIC® 80 mg and ADENURIC® 120 mg are available in packs of 28 film-coated tablets.

Medicine Classification
Prescription Medicine

Sponsor Details
A.Menarini New Zealand Pty Ltd
4 Whetu Place,
Rosedale, 0632
Auckland
New Zealand

Date of Preparation
18 May 2016